ReviewDigestive diseases and sciences2018
Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review.
Review in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug-Induced Liver Injury Network Experience.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Insights into the Biochemical and Immune Mechanisms in Drug-Induced Liver Injury Pathogenesis.Chemical research in toxicology · 2026Review
- Multi-lineage hepatic organoids reveal toxic exosome mediated indirect hepatotoxicity.Nature communications · 2026Article
- Hepatotoxicity Associated with Adalimumab in Hidradenitis Suppurativa: A Report of Two Cases of Drug-Induced Liver Injury.Dermatology practical & conceptual · 2025Article
- [Risk factors of early myocardial injury and the impact of early myocardial injury on prognosis of patients with extensive burns].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Article
- The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity.Cell & bioscience · 2022Review
- Infliximab-Induced Vanishing Bile Duct Syndrome.Cureus · 2022Article
- Hepatocyte-Conditional Knockout of Phosphatidylethanolamine Binding Protein 4 Aggravated LPS/D-GalN-Induced Acute Liver InjuryFrontiers in immunology · 2022Article
- Acute liver failure in Still's disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI.BMC gastroenterology · 2021Article
- Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature.World journal of clinical cases · 2021Article
- Article
- Infliximab-Induced Acute Liver Failure in a Patient With Crohn's Disease Requiring Orthotopic Liver Transplantation.ACG case reports journal · 2021Article
- Luzindole attenuates LPS/d-galactosamine-induced acute hepatitis in mice.Innate immunity · 2020Article
- Liver Histology: Diagnostic and Prognostic Features.Clinics in liver disease · 2020Review
- Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.Hepatology communications · 2020Review
- The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity.Cell death & disease · 2020Article
- Now You See It, Now You Do Not: A Case of Infliximab-Induced Vanishing Bile Duct Syndrome.ACG case reports journal · 2019Article
- Drug-Induced Liver Injury: Highlights of the Recent Literature.Drug safety · 2019Review
- Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond.Clinical liver diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundTumor necrosis factor-α antagonists (anti-TNF-α) have been associated with drug-induced liver injury. However, cases of anti-TNF-α-associated acute liver failure have only been rarely reported.
aimsTo identify cases of anti-TNF-α-associated acute liver failure and evaluate patterns of liver injury and common characteristics to the cases.
methodsThe United States Acute Liver Failure Study Group database was searched from 1998 to 2014. Four subjects were identified. A PubMed search for articles that reported anti-TNF-α-associated acute liver failure identified five additional cases.
resultsThe majority of individuals affected were female (eight of nine cases). Age of individual ranged from 20 to 53 years. The most common anti-TNF-α agent associated with acute liver failure was infliximab (n = 8). The latency between initial drug exposure and acute liver failure ranged from 3 days to over a year. Of the nine cases, six required emergency LT. Liver biopsy was obtained in seven cases with a preponderance toward cholestatic-hepatitic features; none showed clear autoimmune features.
conclusionsAnti-TNF-α-associated acute liver failure displays somewhat different characteristics compared with anti-TNF-α-induced drug-induced liver injury. Infliximab was implicated in the majority of cases. Cholestatic-hepatitic features were frequently found on pre-transplant and explant histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.